BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY
Clinical trials for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Time gene infusion aims to repair hearts in rare genetic condition
Disease control Recruiting nowThis early-stage trial tests a single intravenous dose of AFTX-201, a gene therapy designed to deliver a working copy of the BAG3 gene to heart cells. It enrolls 22 adults aged 18–55 with dilated cardiomyopathy and a BAG3 mutation. The study primarily checks safety and tolerabili…
Matched conditions: BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Affinia Therapeutics • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New gene therapy trial hopes to strengthen hearts in rare genetic condition
Disease control Recruiting nowThis early-stage study tests a one-time gene therapy called ALXN2350 for adults with a specific genetic heart condition (BAG3-related dilated cardiomyopathy). The heart muscle becomes weak and enlarged, making it hard to pump blood. The treatment aims to fix the faulty gene to im…
Matched conditions: BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC